How long does it take to take Jisandai (Bingtonsha) to effectively treat hepatitis C?

Epclusa (Epclusa), as an antiviral drug specially designed for chronic hepatitis C virus (HCV) infection, relies on its unique sofosbuvir (So The compound formula of fosbuvir) and velpatasvir (Velpatasvir) can comprehensively respond to various genotypes of hepatitis C virus, and therefore occupies an important position in the global hepatitis C treatment field.

Under normal circumstances, the treatment cycle of Jisandai (Bingtonsha) is 12 weeks, which means that patients need to take one tablet of the drug every day for 84 days consecutively. This treatment course setting is based on the results of in-depth clinical research, which shows that during this period, Jisanda (Bingtonsa) can effectively eliminate the hepatitis C virus in most patients, and the recurrence rate remains at a low level.

Of course, the length of treatment is not set in stone. For specific patient groups, doctors will make personalized adjustments based on the condition. For example, for first-time treatment patients who do not have cirrhosis, a 12-week course is often sufficient. However, for patients with cirrhosis or those whose previous treatment has not been successful, doctors may consider extending the course of treatment or combining it with other drugs, such as ribavirin, in order to achieve a higher cure rate.

During the treatment period, patients must strictly follow the doctor's instructions and cannot change the length of the treatment course without authorization. Stopping treatment early may lead to incomplete viral clearance and increase the risk of relapse; while unnecessarily prolonging the course of treatment may bring additional side effects and economic burden. At the same time, regular viral load testing is crucial to monitor efficacy and adjust treatment options.

Hepatitis C is generally considered cured for patients who complete the 12 weeks of treatment and test negative for the virus. But even so, regular follow-up is necessary, especially for patients at risk for cirrhosis or other liver diseases, to ensure long-term health.